Results 241 to 250 of about 13,289,433 (300)
Acta Psychiatrica Scandinavica, Volume 154, Issue 4, Page 305-312, October 2026.ABSTRACT Introduction Diabetes, obesity and bipolar disorder often co‐occur and may have shared pathophysiology. Glucagon‐like peptide 1 receptor agonists (GLP‐1RA) treat diabetes and obesity but their impact on bipolar disorder is unknown. In this era of stagnated pharmacotherapy, we examined psychiatric hospitalisation and absence from work due to ...
Heidi Taipale +5 more
wiley +1 more source
The Crosstalk Between Diabetes and Alzheimer's Disease: A Molecular Perspective
Basic &Clinical Pharmacology &Toxicology, Volume 139, Issue 4, October 2026.Increasing evidence indicates an association between type 2 diabetes mellitus and Alzheimer’s disease, contributing to the proposed concept of AD as “type 3 diabetes.” Shared biological features such as impaired insulin signaling, chronic inflammation, mitochondrial dysfunction, and oxidative stress have been observed in both T2DM and AD.
Deniz Catakli +3 more
wiley +1 more source
Comparison of medication persistence and adherence in type 2 diabetes using a once-weekly regimen of DPP-4 inhibitor compared with once-daily and twice-daily regimens: a retrospective cohort study of Japanese health insurance claims data. [PDF]
Diabetol IntMiwa T +4 more
europepmc +1 more source
Diabetes, Obesity and Metabolism, Volume 28, Issue 10, Page 9101-9111, October 2026.ABSTRACT Aims To evaluate the long‐term efficacy and safety of imeglimin added to dipeptidyl peptidase‐4 (DPP‐4) inhibitors in Japanese patients with type 2 diabetes, focusing on glycemic durability and safety in elderly patients over 104 weeks. Materials and Methods This multicenter, randomized, placebo‐controlled trial comprised a 24‐week double ...
Masashi Shimoda +4 more
wiley +1 more source
Risk of Severe Hypoglycemia Associated With Concomitant Use of Sulfonylureas and Amiodarone
Diabetes, Obesity and Metabolism, Volume 28, Issue 10, Page 9336-9345, October 2026.ABSTRACT Aims To evaluate whether initiation of amiodarone while receiving sulfonylurea is associated with an increased risk of severe hypoglycemia compared with the initiation of other antiarrhythmic agents (flecainide, sotalol, or propafenone) while receiving sulfonylurea. Materials and Methods We conducted a population‐based cohort study using South
Sungho Bea +5 more
wiley +1 more source
Diabetes, Obesity and Metabolism, Volume 28, Issue 10, Page 9346-9355, October 2026.ABSTRACT Aim Cardiovascular disease (CVD) is the leading cause of mortality in individuals with diabetes. Diabetic kidney disease, closely related to CVD risk, is prevalent in up to 40% of this population. Emerging evidence suggests ceramide lipids as accurate biomarkers for CVD.
Kristina Pigsborg +10 more
wiley +1 more source
Summary of Research: Efficacy and Safety of the SGLT2 Inhibitor Empagliflozin Versus Placebo and the DPP-4 Inhibitor Linagliptin Versus Placebo in Young People with Type 2 Diabetes (DINAMO): A Multicentre, Randomised, Double-Blind, Parallel Group, Phase 3 Trial. [PDF]
Diabetes TherLaffel LM.
europepmc +1 more source
Diabetes, Obesity and Metabolism, Volume 28, Issue 10, Page 9265-9274, October 2026.ABSTRACT Aims Cardiovascular, kidney and metabolic diseases are pathophysiologically interrelated and are conceptualised within the cardiovascular‐kidney‐metabolic (CKM) syndrome framework. However, evidence linking continuous glucose monitoring (CGM) to CKM syndrome remains limited.
Hang Su +7 more
wiley +1 more source
Diabetes, Obesity and Metabolism, Volume 28, Issue 10, Page 9461-9472, October 2026.ABSTRACT Aim Although finerenone has shown efficacy in randomized trials, evidence from routine clinical practice remains limited. We aimed to assess the real‐world effectiveness and safety of finerenone in people with type 2 diabetes (PWT2D) and chronic kidney disease (CKD), with a particular focus on residual cardiorenal risk as reflected by changes ...
Oscar Moreno‐Pérez +13 more
wiley +1 more source